Denmark, home of Ozempic, feels the drug's effects [Yahoo! Finance]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance
The Danish Medicines Agency announced new restrictions to limit who gets access to a class of diabetes drugs known as GLP-1 antagonists and by their main ingredient, semaglutide. Regulators plan to reduce subsidies and only pay for the drugs if patients can't be treated with cheaper alternative medications. According to the agency, half of type-2 diabetes patients were prescribed GLP-1 drugs without trying other cheaper alternatives in 2023. The most famous GLP-1 drug, Ozempic, is made in Denmark by pharmaceutical giant Novo Nordisk and it has transformed both the country's economy and the company's balance sheet. With a market value now surpassing that of Denmark, Novo Nordisk recently cut Ozempic prices by almost one-third in Denmark, from $188 to $125 per month, after public reimbursement negotiations. But the demand for semaglutide drugs — and especially Ozempic — has surged in Denmark and around the world due to their apparent weight-loss side effects, raising concerns among
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [Yahoo! Finance]Yahoo! Finance
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- Wegovy users may keep the weight off for 4 years, drug's maker says [CBS News]CBS News
- Ozempic maker Novo Nordisk says it will study drug's effects on alcohol consumption but isn't focused on addiction [CNN]CNN
- UK weight-loss drug price rivalry intensifies with Pharmacy2U mark-down [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 5/3/24 - Beat
NVO
Sec Filings
- 5/15/24 - Form 6-K
- 5/13/24 - Form 6-K
- 5/13/24 - Form 6-K
- NVO's page on the SEC website